Everything about Deprenyl totally explained
Selegiline (l-deprenyl, Eldepryl, Zelapar, or Anipryl
veterinary) is a
drug used for the treatment of early-stage
Parkinson's disease and
senile dementia. In normal clinical doses it's a selective irreversible
MAO-B inhibitor, however in larger doses (>20
mg in a typical adult) it loses its specificity and also inhibits MAO-A. Dietary restrictions are common for MAOI treatments, but since selegiline is selective for MAO-B, special dietary restrictions for lower doses have been found to be unnecessary. The drug was researched by
Knoll József. Selegiline is most closely related to the
phenylethylamines. The only difference between the two classes of drugs is the attachment of a
propargyl group (three carbons with a triple bond between the second and third carbon) to the nitrogen.
Uses
It is sometimes used
off-label to treat
narcolepsy and as a
nootropic, as well as for its published life-extending effects among several species of mammals. It is also reported to positively affect
libido, particularly in older
males. As of February 28, 2006, selegiline has also been approved by the
Food and Drug Administration (FDA) to treat
major depression using a transdermal patch (
Emsam Patch). Selegiline is also used (at extremely high dosages relative to humans) in
veterinary medicine to treat the symptoms of
Cushing's disease and so-called "cognitive dysfunction" in
dogs. As of June 26, 2006, a selegiline transdermal patch is being tested for its effectiveness in treating
ADHD.
Several clinical studies are currently underway to evaluate Selegiline's effectiveness in helping people stop smoking
tobacco or
marijuana.
Mechanism of Action
Selegiline is a selective inhibitor of MAO-B; MAO-B metabolizes dopamine. Selegiline exhibits little therapeutic benefit when used independently, but enhances and prolongs the anti-
Parkinson effects of
levodopa.
Metabolites
Desmethylselegiline
Desmethylselegiline may have neuroprotective antiapoptotic properties. A large multicenter study suggests a decrease of in the disease progression of parkinsonism but may have reflected other symptomatic response. Desmethylselegiline is metabolized by
CYP2C19.
L-amphetamine and L-methamphetamine
Selegiline is partly
metabolized to l-methamphetamine, a
stereoisomer of
methamphetamine in vivo. A characteristic metabolic pattern was noted, exemplified by a ratio of 1-methamphetamine to 1-amphetamine of about 2.8. This stereoisomer isn't considered psychoactive and has little abuse potential. The stimulatory effect on locomotor activity and dopamine synthesis may be contributed to by the action of l-methamphetamine.
Due to this metabolite selegiline can cause false positives for
amphetamine/
methamphetamine on drug tests.
Legal Issues
Possibly due to the structural similarity to illegal
stimulants, selegiline has been classified as a
controlled substance in
Japan and thus can only be obtained with a
prescription or special government license. Selegiline isn't a controlled substance in the US but a prescription is required to obtain it.
Emsam
February 28, 2006 - The Food and Drug Administration approved Emsam (selegiline), the first skin (transdermal) patch for use in treating major depression. The once a day patch works by delivering selegiline, a monoamine oxidase inhibitor or MAOI, through the skin and into the bloodstream. At its lowest strength, Emsam can be used without the dietary restrictions that are needed for all oral MAO inhibitors that are approved for treating major depression. It comes in three sizes that deliver 6, 9, or 12 mg of selegiline per 24 hours. The patch is a matrix containing three layers consisting of a backing, and adhesive drug layer, and a release liner that's placed against the skin. EMSAM was developed by Somerset Pharmaceuticals, Inc. In December 2004, Bristol-Myers Squibb and Somerset entered into an agreement that provides Bristol-Myers Squibb with distribution rights to market EMSAM after approval in the United States.
Zelapar
Zelapar is a transmucosal preparation for human administration of selegiline. The quickly-dissolving lozenge is placed between cheek and gum and the medication enters the bloodstream directly. Because hepatic first-pass metabolism is bypassed, the effective dose is lower than oral (swallowed) selegiline. GI side effects are reportedly reduced compared to oral (swallowed) selegiline. Zelapar is manufactured by
Valeant Pharmaceuticals (External Link
).
Further Information
Get more info on 'Deprenyl'.
|
External Link Exchanges
Do you know how hard it is to get a link from a large encyclopaedia? Well we're different and will prove it. To get a link from us just add the following HTML to your site on a relevant page:
<a href="http://selegiline.totallyexplained.com">Selegiline Totally Explained</a>
Then simply click through this link from your web page. Our crawlers will verify your link, extract the title of your web page and instantly add a link back to it. If you like you can remove the words Totally Explained and embed the link in article text.
As long as your link remains in place, we'll keep our link to you right here. Please play fair - our crawlers are watching. Your site must be closely related to this one's topic. Any kind of spamming, dubious practises or removing the link will result in your link from us being dropped and, potentially, your whole site being banned. |